BUZZ-Morgan Stanley bullish on Generate Biomedicines, cites strength of lead asthma drug

Reuters

Yesterday

BUZZ-<a href="https://laohu8.com/S/MSPQL">Morgan Stanley</a> bullish on <a href="https://laohu8.com/S/GENB">Generate Biomedicines</a>, cites strength of lead asthma drug

** Morgan Stanley initiates drug developer Generate Biomedicines GENB.O with an "overweight" rating as research quiet period ends

** Company secured a valuation of nearly $1.91 bln at open after its debut on the Nasdaq late last month

** Brokerage cites, "we see GENB's lead asset, GB-0895, as having best-in-class potential vs. blockbuster generating commercial benchmarks"

** GB-0895 is GENB's lead product to treat severe asthma which is being tested in a late-stage trial

** "We believe GB-0895 has credible best-in-class potential in severe asthma by improving on a validated mechanism rather than reinventing the biology"- MS

** Goldman Sachs, Morgan Stanley, Piper Sandler, Guggenheim Securities and Cantor were the underwriters for GENB's offering

** As of last close, stock down 24% since its debut on Feb. 27

(Reporting by Pragyan Kalita in Bengaluru)

((Pragyan.Kalita@thomsonreuters.com;))

At the request of the copyright holder, you need to log in to view this content

LOGIN / SIGN UP

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/2622006872"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2622006872\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2622006872?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-26 01:52","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2622006872","market":"us","top_or_hot":-1,"title":"BUZZ-Morgan Stanley bullish on Generate Biomedicines, cites strength of lead asthma drug","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-<a href=\"https://laohu8.com/S/MSPQL\">Morgan Stanley</a> bullish on <a href=\"https://laohu8.com/S/GENB\">Generate Biomedicines</a>, cites strength of lead asthma drug</title></head><body><p>** <a href=\"https://laohu8.com/S/MSPQV\">Morgan Stanley</a> initiates drug developer Generate Biomedicines <span>GENB.O</span> with an \"overweight\" rating as research quiet period ends</p><p>** Company <span>secured a valuation</span> of nearly $1.91 bln at open after its debut on the Nasdaq late last month</p><p>** Brokerage cites, \"we see GENB's lead asset, GB-0895, as having best-in-class potential vs. blockbuster generating commercial benchmarks\"</p><p>** GB-0895 is GENB's lead product to treat severe asthma which is being tested in a late-stage trial </p><p>** \"We believe GB-0895 has credible best-in-class potential in severe asthma by improving on a validated mechanism rather than reinventing the biology\"- MS</p><p>** Goldman Sachs, <a href=\"https://laohu8.com/S/MSSXV\">Morgan Stanley</a>, Piper Sandler, Guggenheim Securities and Cantor were the underwriters for GENB's offering</p><p>** As of last close, stock down 24% since its debut on Feb. 27</p><p> (Reporting by Pragyan Kalita in Bengaluru)</p><p> ((Pragyan.Kalita@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BUZZ-Morgan Stanley bullish on Generate Biomedicines, cites strength of lead asthma drug</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBUZZ-Morgan Stanley bullish on Generate Biomedicines, cites strength of lead asthma drug\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-03-26 01:52</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-<a href=\"https://laohu8.com/S/MSPQL\">Morgan Stanley</a> bullish on <a href=\"https://laohu8.com/S/GENB\">Generate Biomedicines</a>, cites strength of lead asthma drug</title></head><body><p>** <a href=\"https://laohu8.com/S/MSPQV\">Morgan Stanley</a> initiates drug developer Generate Biomedicines <span>GENB.O</span> with an \"overweight\" rating as research quiet period ends</p><p>** Company <span>secured a valuation</span> of nearly $1.91 bln at open after its debut on the Nasdaq late last month</p><p>** Brokerage cites, \"we see GENB's lead asset, GB-0895, as having best-in-class potential vs. blockbuster generating commercial benchmarks\"</p><p>** GB-0895 is GENB's lead product to treat severe asthma which is being tested in a late-stage trial </p><p>** \"We believe GB-0895 has credible best-in-class potential in severe asthma by improving on a validated mechanism rather than reinventing the biology\"- MS</p><p>** Goldman Sachs, <a href=\"https://laohu8.com/S/MSSXV\">Morgan Stanley</a>, Piper Sandler, Guggenheim Securities and Cantor were the underwriters for GENB's offering</p><p>** As of last close, stock down 24% since its debut on Feb. 27</p><p> (Reporting by Pragyan Kalita in Bengaluru)</p><p> ((Pragyan.Kalita@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"PIPR","symbol_name":"派杰投资","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260325:nL4N40D1S9:1","article_id":"2622006872","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2622006872","pubTimestamp":1774461124,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BUZZ-Morgan Stanley bullish on Generate Biomedicines, cites strength of lead asthma drug** Morgan Stanley initiates drug developer Generate Biomedicines GENB.O with an \"overweight\" rating as research quiet period ends** Company secured a valuation of nearly $1.91 bln at open after its debut on the Nasdaq late last month** Brokerage cites, \"we see GENB's lead asset, GB-0895, as having best-in-class potential vs. blockbuster generating commercial benchmarks\"** GB-0895 is GENB's lead product to treat severe asthma which is being tested in a late-stage trial ** \"We believe GB-0895 has credible best-in-class potential in severe asthma by improving on a validated mechanism rather than reinventing the biology\"- MS** Goldman Sachs, Morgan Stanley, Piper Sandler, Guggenheim Securities and Cantor were the underwriters for GENB's offering** As of last close, stock down 24% since its debut on Feb. 27  ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"PIPR":"派杰投资","LU0053671581.USD":"摩根大通美国小盘成长股 A(dist)","GENB":"Generate Biomedicines","BK4139":"生物科技","BK4127":"投资银行业与经纪业"},"translate_title":"BUZZ-摩根士丹利看好Generate Biomedicines，并引用了主要哮喘药物的实力","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"GENB":0.9,"PIPR":0.9},"content_text":"BUZZ-Morgan Stanley bullish on Generate Biomedicines, cites strength of lead asthma drug** Morgan Stanley initiates drug developer Generate Biomedicines GENB.O with an \"overweight\" rating as research quiet period ends** Company secured a valuation of nearly $1.91 bln at open after its debut on the Nasdaq late last month** Brokerage cites, \"we see GENB's lead asset, GB-0895, as having best-in-class potential vs. blockbuster generating commercial benchmarks\"** GB-0895 is GENB's lead product to treat severe asthma which is being tested in a late-stage trial ** \"We believe GB-0895 has credible best-in-class potential in severe asthma by improving on a validated mechanism rather than reinventing the biology\"- MS** Goldman Sachs, Morgan Stanley, Piper Sandler, Guggenheim Securities and Cantor were the underwriters for GENB's offering** As of last close, stock down 24% since its debut on Feb. 27 (Reporting by Pragyan Kalita in Bengaluru) ((Pragyan.Kalita@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"shareholding,productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}